Novel linear DNA vaccines induce protective immune responses against lethal infection with influenza virus type A/H5N1.

ABSTRACT: Vaccine development for possible influenza pandemics has been challenging. Conventional vaccines such as inactivated and live attenuated virus preparations are limited in terms of production speed and capacity. DNA vaccination has emerged as a potential alternative to conventional vaccines against influenza pandemics. In this study, we use a novel, cell-free DNA manufacturing process (synDNA) to produce prototype linear DNA vaccines against the influenza virus type A/H5N1. This synDNA process does not require bacterial fermentation, so it avoids the use of antibiotic resistance genes and other nucleic acid sequences unrelated to the antigen gene expression in the actual therapeutic DNA construct. The efficacy of various vaccines expressing the hemagglutinin and neuraminidase proteins (H5N1

SUBMITTER: Kendirgi F 

PROVIDER: S-EPMC2597034 | biostudies-literature | 2008 Nov-Dec

REPOSITORIES: biostudies-literature